Escape Bio, a spinout of Gladstone Institutes, has secured the return of Osage University Partners, Novartis, Novo and Johnson & Johnson.
Escape Bio, a US-based biotherapeutics spinout of Gladstone Institutes targeting neurodegenerative diseases, raised $73m in crossover financing on Monday from investors including spinout-focused investment firm Osage University Partners (OUP).
Pharmaceutical firms Novo, Johnson & Johnson and Novartis also participated, with the latter two investing through their respective subsidiaries Johnson & Johnson Innovation – JJDC and Novartis Venture Fund.
The round was led by Wellington Management Company and also featured Avidity Partners, Cam Capital, New Leaf Ventures, Rock Springs…
